Cenna Biosciences is focused on developing Nubytide, a novel peptide drug aimed at preventing and treating Alzheimer's disease through a unique mechanism that inhibits the production of amyloid-beta (Aß). This innovative approach not only targets Aß but also reduces markers of inflammation and Tau pathology, which are critical factors in the progression of Alzheimer's. The company emphasizes the affordability and ease of administration of Nubytide, positioning it as a differentiated and disease-modifying therapy compared to existing monoclonal antibody treatments that are often more expensive and complex to administer.

The market potential for Nubytide is significant, with over 55 million people globally affected by Alzheimer's disease, a number projected to rise sharply in the coming decades. Cenna Biosciences has established a strong intellectual property position with multiple patents issued in the U.S. and internationally, supporting the uniqueness of their technology. The company is actively advancing Nubytide through clinical development, with plans for an Investigational New Drug (IND) filing in 2024 and proof of concept expected by 2026-27, highlighting their commitment to addressing the urgent need for effective Alzheimer's treatments.

United States

Cenna Biosciences is revolutionizing Alzheimer's treatment with proprietary small peptides and molecules that inhibit beta amyloid production. The company is focused on developing disease-modifying drugs for Alzheimer's disease using a proprietary novel mechanism.

Cenna Biosciences

Company Details